Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DWJ211 in Healthy Volunteers
NCT04159961Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Dec 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sodium deoxycholate in submental fat and abdominal obesity (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 24 hours, Time to Maximum Plasma Concentration at 24 hours and 1 more. Started Dec 2019; status: completed.
02
Drugs
sodium deoxycholate
03
Conditions
submental fatabdominal obesity
Beyond the preview
Go deeper on NCT04159961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159961.